Sign in
Taking peoplePhase 4

IBI311 for thyroid eye disease that is no longer active

Tests IBI311 in adults with inactive moderate to severe thyroid-associated ophthalmopathy.

Key facts

Who runs it
Shanghai Changzheng Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Registry title
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Status
Recruiting
Phase
Phase 4
People taking part
50 people, planned
Started
15 Apr 2025
Expected to end
15 Apr 2035
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • IBI311
  • Follew-up
Record updated
3 September 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Diagnosed with TAO by Bartley criteria
  • Moderate to severe patients defined by EUGOGO
  • CAS <3 (on the 7-item scale) for the study eye
  • Participant with intractable diplopia, or incomplete closure of both eyes, or requiring further surgical intervention
  • Participant with a strong willingness for further intervention

Who cannot take part

  • Receive orbital radiotherapy or surgical treatment for TED, including orbital decompression, strabismus surgery and eyelid retraction correction
  • Screening for poorly controlled hypertension, with systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; Or adjust the antihypertensive drug (dosage or type of drug) within 30 days before screening; Evidence of renal artery stenosis or unstable blood pressure (including orthostatic hypotension, etc.)
  • During the screening period, if either ear has a history of tinnitus or other hearing impairment; Or abnormal pure tone audiometry results (defined as an average bone conduction hearing threshold of ≥25 dB at 0.5, 1, 2, 4 kHz or a bone conduction hearing threshold of ≥40 dB at any frequency)
  • At the time of screening, the 12-lead ECG showed a heart rate of < 50 beats/min or > 100 beats/min. The ECG indicated active heart disease, or the researchers believed that the abnormal ECG at the time of screening would interfere with the interpretation of the ECG results in the subsequent follow-up process. Especially, QTcF > 450 ms (for men) and QTcF > 470 ms (for women) should be excluded
  • HIV antibody or HCV antibody positive individuals or those with active syphilis (defined as those with positive non-specific syphilis antibodies or those who need anti-syphilis treatment after consultation by the infectious disease department)
  • Any major illness/condition or evidence of an unstable clinical condition that, in the investigators judgment, will substantially increase the risk to the participant, or confound the interpretation of safety assessments, if they were to participate in the study
  • Any other condition that, in the opinion of the investigator, would impair the ability of the participant to comply with the study procedures or impair the ability to interpret data from the participants participation in the study
  • At the time of screening, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times ULN, or accompanied by active hepatitis B (defined as HBsAg positive with HBV-DNA load greater than 1000 IU/ mL), or being receiving anti-hepatitis B virus treatment
  • During screening, the Glomerular Filtration Rate (GFR) was < 30 ml/ min/1.73m2 (using the MDRD formula: GFR =186× serum creatinine (mg/ dl) -1.154× (age) -0.203× (0.742 [if female]), unit conversion of serum creatinine: 1 μmol/L=0.0113 mg/dL); 10) At the time of screening, there was poorly controlled diabetes (defined as glycated hemoglobin ≥7.0% at the time of screening, or a new diabetes drug [oral or injection] or a dose change of the current prescribed diabetes drug > 10% within 60 days before screening)
  • Anticipated need for intervention due to sight-threatening complications or other significant and acute deterioration in vision
  • Combined with other lesions in the orbit
  • Pregnant or lactating

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Thyroid-associated ophthalmopathy (TAO) is an organ-specific autoimmune disease closely related to thyroid disease, which leads the incidence of orbital disease in adults and is the most common cause of diffuse toxic goiter (Graves disease, GD). The clinical manifestations of TAO are complex and varied. In severe cases, it may seriously impair visual function, affect daily life, and even cause corneal ulceration, perforation, and blindness. Therefore, a reasonable and effective treatment plan should be chosen according to the degree of TAO.

Read full original descriptionShow less

IBI311 is a fully human monoclonal insulin-like growth factor-1 receptor inhibitory antibody. It has binding activity against IGF-1R positive cells, can block the binding of IGF-1 and IGF-2 to IGF-1R, and has a dose-dependent effect. It can inhibit the proliferation of HT29 cells caused by the activation of the IGF-1R signaling pathway. Meanwhile, it can dose-dependently inhibit the proliferation of orbital fibroblasts and the secretion of hyaluronic acid (HA) in patients with TAO.

However, there are still significant gaps in the existing research evidence: There is a lack of reports on the efficacy and safety of IBI311 in inactive moderate to severe TAO patients.

The aim of this clinical study is to:

1. To evaluate the efficacy of IBI311 treatment in patients with inactive moderate to severe TAO. 2. To observe the safety of IBI311 treatment in patients with inactive moderate to severe TAO.

The 2 groups in the trial

  • IBI311Existing treatment, for comparison

    Participants with inactive thyroid ophthalmopathy will 8 infusions of IBI1311 (10 mg/kg for the first infusion and 20 mg/kg for the remaining 7 infusions),The interval between each treatment is 3 weeks. After completing 4 treatments, observe for 3 months before entering the next stage of treatment。

  • Follow-upOther group

    Participants with inactive thyroid ophthalmopathy will only receive follow-up every six months.

    Treatment: Follew-up

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluation of the Efficacy and Safety Observation of IBI311 Treatment in Patients With Inactive TAO
Plain-language title
IBI311 for thyroid eye disease that is no longer activeGenerated from the registry record. The registry title is the official one.
Fit questions
Built from NCT07152392, who can take part
Record updated
3 September 2025